Home Corporate Products Customer
Service
Training Investor
Relations
Contract
Manufacturing
Resources
 
 

American Bio Medica Corporation 1st Quarter 2009 Conference Call

KINDERHOOK, N.Y. -- (BUSINESS WIRE) -- May 12, 2009 -- American Bio Medica Corporation (NASDAQ: ABMC), a global provider of immunoassay diagnostic test kits, will release 1st Quarter 2009 results at close of market on Wednesday, May 13, 2009 and will hold its conference call to discuss the 1st Quarter results on Thursday, May 14 2009, at 11 AM Eastern Time (10 AM Central Time).

This call is being webcast by Thomson/CCBN and can be accessed at ABMC’s Web site at www.abmc.com/investor/

Investors and interested parties are invited to participate. The webcast will be in listen-only mode. Listeners are requested to be online at least fifteen minutes early to register, as well as to download and install any complimentary audio software that might be required.

To ask questions, you are invited to participate by phone. Within the United States, dial 1-800-533-7619 and internationally, dial 785-830-1923.

The call will be available for replay on the company’s website at www.abmc.com/investor/ for 30 days.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson Street Events (www.streetevents.com), a password-protected event management site.

About ABMC

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid One®, Rapid TEC®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® products test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

American Bio Medica Corporation
Melissa Waterhouse, 518-758-8158, x107
mdwaterhouse@abmc.com